Preparation of glibenclamide nanocrystals by a simple laboratory scale ultra cryo-milling
Source abstract
Abstract
The objective of this study is to evaluate the ability to reduce the particle size of glibenclamide (GBC) to the nanometric scale through a very simple and well-known laboratory scale method, the laboratory scale ultra cryo-milling. The effect of milling on GBC crystalline properties and dissolution behaviour was deliberately evaluated in the absence of any surfactants as stabilizers. The milling procedure consisted in adding particles to liquid nitrogen and milling them by hand in a mortar with a pestle for different time intervals (15, 30, 40 min). For comparison, the same milling procedure was also applied without liquid nitrogen. The particle size reduction was evaluated for the coarsest samples (>3 μm) by measuring the particle Ferret’s diameter through scanning electron microscopy, while for the smallest one (<3 μm) by dynamic light scattering. A time grinding of 40 min in the presence of liquid nitrogen was revealed highly efficacious to obtain particles of nanodimensions, with a geometric mean particle size of 0.55 ± 0.23 μm and more than the 80 % of particles lower than 1,000 nm. Interestingly, non-agglomerated particles were obtained. Differential scanning calorimetry and X-ray powder diffractometry allowed to assess that under mechanical treatment no polymorphic transitions were observed, while a decrease in crystallinity degree occurred depending on the milling procedure (presence or absence of liquid nitrogen) and the milling time (crystallinity decreases at increasing milling time from 15 to 40 min). A comparison of the intrinsic dissolution rate and the dissolution from particles revealed an interesting improvement of particle dissolution particularly for particles milled in the presence of liquid nitrogen due to an increase in particle surface area and concentration gradient, according to the Noyes–Whitney equation.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Crystallization and Solubility Studies · Protein purification and stability
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (30)
Show source-provided references
1. Ambike AA, Mahadik KR, Paradkar A (2004) Stability study of amorphous valdecoxib. Int J Pharm 282:151–16210.1016/j.ijpharm.2004.06.009 ↗
2. Arnquist HJ, Karlberg BE, Melander A (1983) Pharmacokinetics and effects of glibenclamide in two formulations, HB 419 and HB 420, in type 2 diabetes. Ann Clin Res 37:21–25
3. Banakar UV (1992) Pharmaceutical dissolution testing. Marcel Dekker, New YorK, pp 55–105
4. Borchert H, Müller H, Pfeifer S (1976) Zur biologischen verfugbarkeit von glibenclamide in abhangigkeit von der teilchengrosse. Pharmazie 31:307–309
5. Chalk JB, Patterson M, Smith MT, Eadie MJ (1986) Correlation between in vitro dissolution, in vivo bioavailability and hypoglycemic effect of oral glibenclamide. Eur J Clin Pahrmacol 31:177–18210.1007/BF00606655 ↗
6. Crowley KJ, Zografi G (2002) Water vapour absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions. J Pharm Sci 90:2150–216510.1002/jps.10205 ↗
7. Dressman J, Butler J, Hempenstall J, Reppas C (2001) The BCS: where do we go from here? Pharm Technol 7:68–76
8. Gao L, Zhang D, Chen M (2008) Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res 10:845–86210.1007/s11051-008-9357-4 ↗
9. Gashi Z, Censi R, Malaj L, Gobetto R, Mozzicafreddo M, Angeletti M, Masic A, Di Martino P (2009) Differences in the interaction between aryl propionic acid derivatives and poly(vinylpyrrolidone) K30: a multi-methodological approach. J Pharm Sci 98:4216–422810.1002/jps.21734 ↗
10. Ghosh I, Bose S, Vippagunta R, Harmon F (2011) Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm 409:260–26810.1016/j.ijpharm.2011.02.051 ↗
11. Hartke K (2001) Comments to the European pharmacopoeia, 14th edn. Stuttgart, WVG mbH
12. ICH Q1A(R2) (2003) International Conference on Harmonization, Stability testing of new drug substances and products
13. Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360–37210.1001/jama.287.3.360 ↗
14. Jimbo G (1986) Recent formulation technologies and their application. Iyaku Journal Inc, Tokyo, p 168
15. Junghanns JHAH, Müller RH (2008) Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 3:295–309
16. Kakran M, Shegokar R, Sahoo NG, Gohla S, Li L, Müller RH (2012) Long-term stability of quercetin nanocrystals prepared by different methods. J Pharm Pharmacol 64:1392–140210.1111/j.2042-7158.2012.01515.x ↗
17. Leuner C, Dressman J (2000) Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47–6010.1016/S0939-6411(00)00076-X ↗
18. Liu P, Rong X, Laru J, Veen BV, Kiesvaara J, Hirvonen J, Laaksonen T, Peltonen L (2011) Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int J Pharm 411:215–22210.1016/j.ijpharm.2011.03.050 ↗
19. Martena V, Censi R, Hoti E, Malaj L, Di Martino P (2012a) A new nanospray drying method for the preparation of nicergoline pure nanoparticles. J Nanopart Res 14:934–94410.1007/s11051-012-0934-1 ↗
20. Martena V, Censi R, Hoti E, Malaj L, Di Martino P (2012b) Indomethacin nanocrystals prepared by different laboratory scale methods: effect on crystalline form and dissolution behavior. J Nanopart Res 14:1275–128910.1007/s11051-012-1275-9 ↗
21. Mauludin R, Müller RH, Keck CM (2009) Development of an oral rutin nanocrystal formulation. Int J Pharm 370:202–20910.1016/j.ijpharm.2008.11.029 ↗
22. Mitri K, Shegokar R, Gohla S, Anselmi C, Müller RH (2011) Lutein nanocrystals as antioxidant formulation for oral and dermal delivery. Int J Pharm 420:141–14610.1016/j.ijpharm.2011.08.026 ↗
23. Nanjwade BK, Derkar GK, Bechra HM, Nanjwade VK, Manvi FV (2011) Design and characterization of lovastatin for solubility and dissolution enhancement. Nanomed Nanotechnol 2:1–7
24. Niwa T, Nakanishi Y, Danjo K (2010) One-step preparation of pharmaceutical nanocrystals using ultra cryo-milling technique in liquid nitrogen. Eur J Pharm Sci 41:78–8510.1016/j.ejps.2010.05.019 ↗
25. Noyes A, Whitney WR (1897) The rate of solution of solid substances in their own solutions. J Am Chem Soc 19:930–93410.1021/ja02086a003 ↗
26. Shegokar R, Müller RH (2010) Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 399:129–13910.1016/j.ijpharm.2010.07.044 ↗
27. Shimpi SL, Chauhan B, Mahadik KR, Paradkar A (2005) Stabilization and improved in vivo performance of amorphous etoricoxib using Gelucire 50/13. Pharm Res 22:1727–173410.1007/s11095-005-6694-1 ↗
28. Verma S, Kumar S, Gokhale R, Burgess DJ (2011) Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening. Int J Pharm 406:145–15210.1016/j.ijpharm.2010.12.027 ↗
29. Watanabe T, Wakiyama N, Usui F, Ikeda M, Isobe T, Senna M (2001) Stability of amorphous indomethacin compounded with silica. Int J Pharm 226:81–9110.1016/S0378-5173(01)00776-1 ↗
30. Wojnarowska Z, Grzybowska K, Adrjanowicz K, Kaminski K, Paluch P, Hawelek L, Wrzalik R, Dulski M (2010) Study of the amorphous glibenclamide drug: analysis of the molecular dynamics of quenched and cryomilled material. Mol Pharm 7:1692–170710.1021/mp100077c ↗